Aranda-Abreu Gonzalo Emiliano, Rojas-Durán Fausto, Hernández-Aguilar María Elena, Herrera-Covarrubias Deissy, Chí-Castañeda Lizbeth Donají, Toledo-Cárdenas María Rebeca, Suárez-Medellín Jorge Manuel
Instituto de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa 91192, Mexico.
Geriatrics (Basel). 2024 Jun 22;9(4):86. doi: 10.3390/geriatrics9040086.
Alzheimer's disease was described more than 100 years ago and despite the fact that several molecules are being tested for its treatment, which are in phase III trials, the disease continues to progress. The main problem is that these molecules function properly in healthy neurons, while neuronal pathology includes plasma membrane disruption, malfunction of various organelles, and hyperphosphorylation of Tau and amyloid plaques. The main objective of this article is the discussion of a neuronal restoration therapy, where molecules designed for the treatment of Alzheimer's disease would probably be more effective, and the quality of life of people would be better.
阿尔茨海默病在100多年前就有记载，尽管目前有几种分子正在进行治疗该疾病的III期试验，但病情仍在进展。主要问题在于这些分子在健康神经元中能正常发挥作用，而神经元病理包括质膜破坏、各种细胞器功能异常以及Tau蛋白过度磷酸化和淀粉样斑块。本文的主要目的是探讨一种神经元修复疗法，针对阿尔茨海默病设计的分子可能在此疗法中更有效，进而改善患者的生活质量。
